Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Tiemonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 12/20 | 0.47 |
| ▸ | CHRM1 known ✓ | P11229 | 8/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.47 |
| ▸ | RGS12 | O14924 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | ICMT | O60725 | 1/20 | 0.37 |
| ▸ | APOBEC3A | P31941 | 3/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TERT | O14746 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tiemonium SCHEMBL250702 | 0.99 | CHRM3 (0.45) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiemonium SCHEMBL1308366 | 0.89 | RGS12 (0.40) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Iodide SCHEMBL3366197 | 0.86 | RGS12 (0.41) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Thiphenamil SCHEMBL7749726 | 0.80 | MAPT (0.49) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Iodide SCHEMBL29558329 | 0.72 | CHRM2 (0.83) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL27463664 | 0.70 | CHRM3 (0.42) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Bromide SCHEMBL4467207 | 0.64 | CHRM3 (0.84) | CHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL4467210 | 0.64 | CHRM3 (0.84) | CHRM3CHRM2CHRM1 | |
| Dotefonium SCHEMBL29387913 | 0.64 | CHRM3 (0.41) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Dotefonium SCHEMBL2733352 | 0.63 | CHRM3 (0.41) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 695 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4154879-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NICOTINE WITHDRAWAL SYMPTOMS | KOREA INST SCI & TECH (KR) | 2025-09-10 | — | — | EP | claimed |
| CN-119315239-A | Miniaturized high-power gain two-stage pulse compression energy multiplier | 散裂中子源科学中心 | 2025-01-14 | — | — | CN | claimed |
| CN-112684772-B | Heat balance control system and method for aluminum oxide dissolution | 贵阳振兴铝镁科技产业发展有限公司 | 2024-05-03 | — | — | CN | claimed |
| EP-3651805-B1 | SOLUBILISATE WITH CURCUMIN AND AT LEAST ONE OTHER ACTIVE SUBSTANCE | AQUANOVA AG (DE) | 2023-10-25 | — | — | EP | claimed |
| EP-3820528-B1 | SOLUBILISATE COMPRISING CURCUMIN AND AT LEAST ONE CANNABINOID AS A FURTHER ACTIVE AGENT | AQUANOVA AG (DE) | 2023-08-30 | — | — | EP | claimed |
| EP-3820529-B1 | SOLUBILISATE WITH CURCUMIN AND AT LEAST THE CANNABINOID THC AS A FURTHER ACTIVE AGENT | AQUANOVA AG (DE) | 2023-08-23 | — | — | EP | claimed |
| CN-116488601-A | Mixed radio frequency multiplexer based on 5G millimeter wave low-loss broadband wireless mode utilizing waveguide cavity Ka wave band | 伊兰泰克公司 | 2023-07-25 | — | — | CN | claimed |
| US-20230223962-A1 | RF MULTIPLEXER OF 5G MMWAVE LOW-LOSS BROADBAND WIRELESS HYBRID TYPE USING WAVEGUIDE CAVITY KA-BAND | ERANGTEK (KR) | 2023-07-13 | — | — | US | claimed |
| EP-4154879-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NICOTINE WITHDRAWAL SYMPTOMS | Korea Institute of Science and Technology (KR) | 2023-03-29 | — | — | EP | claimed |
| US-11065205-B2 | Immediate/delayed drug delivery | DRUG DELIVERY INTERNATIONAL LIMITED (GB) | 2021-07-20 | — | — | US | claimed |
| WO-2009018169-A1 | SUBSTITUTED CYCLOHEXANOLS | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | claimed |
| US-20090028873-A1 | SUBSTITUTED CYCLOHEXANOLS | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-01-29 | — | — | US | claimed |
| EP-1879578-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV Pharmaceutical Inc. (US) | 2008-01-23 | — | — | EP | claimed |
| WO-2006102029-A9 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV PHARMACEUTICAL INC (US) | 2006-12-07 | — | — | WO | claimed |
| WO-2006102029-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV PHARMACEUTICAL, INC. (US) | 2006-09-28 | — | — | WO | claimed |
| EP-1273301-B1 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON SA (CH) | 2006-09-06 | — | — | EP | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090028873-A1 | SUBSTITUTED CYCLOHEXANOLS | OPRM1, OPRD1, OPRK1 | CHRM3 94/4885CHRM1 120/4885CHRM2 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.